The Peutz-Jeghers syndrome (PJS) market is a specialized and rapidly growing segment within the rare genetic disorder therapeutics landscape, focused on a condition that significantly increases the risk of gastrointestinal polyps and various cancers. The Peutz-Jeghers syndrome market is experiencing robust growth, driven by advancements in genetic research, increased awareness among healthcare providers, and a rising demand for targeted therapies. Valued at USD 0.67 billion in 2024, the market is projected to reach USD 1.70 billion by 2035, at a CAGR of 8.82%. This growth reflects a concerted effort to improve early diagnosis, surveillance, and management for patients with this complex condition.

PJS is an autosomal dominant disorder caused by mutations in the STK11 gene, characterized by mucocutaneous pigmentation and the development of hamartomatous polyps in the gastrointestinal tract. The market is segmented by diagnosis method, with genetic testing currently holding the largest share. This dominance is driven by the critical role of identifying STK11 mutations for confirming diagnosis and guiding surveillance strategies. However, endoscopy is the fastest-growing diagnostic segment, reflecting its essential role in directly visualizing and managing polyps, a key aspect of preventing complications. In treatment, surgery remains the largest segment for managing obstructive polyps, while medication is the fastest-growing, spurred by research into targeted therapies.

Key drivers of this market include the growing incidence of PJS and a rising demand for targeted therapies that address the underlying genetic causes. Advancements in genetic testing technologies are facilitating earlier and more accurate diagnoses. Furthermore, a heightened focus on preventive healthcare is encouraging proactive surveillance and management. For a comprehensive understanding of these dynamics, exploring the Peutz-Jeghers syndrome market provides essential insights.